Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?
This trial is active, not recruiting.
|Conditions||st-elevation myocardial infarction, acute myocardial infarction|
|Sponsor||Medstar Research Institute|
|Start date||October 2013|
|End date||October 2014|
|Trial size||800 participants|
|Trial identifier||NCT01991366, Integrilin Stemi|
The aim of this observational study is to evaluate the in hospital and 6 month outcomes of the use of Glycoprotein IIb/IIIa inhibitor eptifibatide as adjunctive therapy in patients undergoing primary Percutaneous Coronary Intervention for ST-elevation myocardial infarction in a large tertiary referral center.
It is hypothesized that Glycoprotein IIb/IIIa inhibitor use during primary Percutaneous Coronary Intervention for ST-elevation myocardial infarction/ acute myocardial infarction is superior to unfractionated heparin alone or bivalirudin alone. Additionally, after propensity matching this superiority remains.
|Observational model||case control|
Receive eptifibatide pre PCI
Receive eptifibatide during PCI
Receive no eptifibatide
All-cause mortality and composite or Q-wave myocardial infarction
time frame: Chart review 6 months after PCI
TIMI major bleeding
time frame: During hospital stay; average stay is less than 48 hours
Male or female participants of any age.
Inclusion Criteria: - Underwent Percutaneous Coronary Intervention at Washington Hospital Center since September 2000 - Either received eptifibatide pre-or during PCI or have received no eptifibatide. Exclusion Criteria: - Patients who received a thrombolytic prior to Percutaneous Coronary Intervention.
|Official title||Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction?|
|Principal investigator||Ron Waksman, MD|
|Description||This is a retrospective, observational, data analysis of approximately 800 patients who underwent primary Percutaneous Coronary Intervention at our institution since September 2000. Patients will have either received eptifibatide pre-or during Percutaneous Coronary Intervention or have received no eptifibatide. Patients who received a thrombolytic prior to Percutaneous Coronary Intervention will be excluded. This analysis is estimated to take 1-2 months.|
Call for more information